Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.79 |
| ▸ | EED | O75530 | 1/20 | 0.63 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.63 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.63 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.63 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20749674 | 0.91 | EZH2 (0.70) | EZH2 | |
| SCHEMBL17305551 | 0.90 | EZH2 (0.74) | EZH2 | |
| SCHEMBL15838992 | 0.90 | EZH2 (0.74) | EZH2 | |
| SCHEMBL17201401 | 0.90 | EZH2 (0.74) | EZH2 | |
| SCHEMBL15871025 | 0.90 | EZH2 (0.79) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13282036 | 0.88 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13467767 | 0.87 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15871024 | 0.86 | EZH2 (0.71) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13468083 | 0.86 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15710322 | 0.85 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382234-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-07-05 | — | — | US | claimed |
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-29 | — | — | US | claimed |
| EP-2931707-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline LLC (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2014107277-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-07-10 | — | — | WO | claimed |
| US-9382234-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2931707-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014107277-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | EZH2 1/4885EED 5/4885RBBP4 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.